当前位置: X-MOL首页全球导师 海外导师 › Wender, Paul A.

个人简介

Education: B.S., 1969, Wilkes College; Ph.D., 1973, Yale University Awards: N.I.H. Postdoctoral Fellow, 1974, Columbia University; A. P. Sloan Fellow, 1979; Dreyfus Teacher Scholar, 1980; Ernest Guenther Award, 1988; ICI Pharmaceutical Group's Stuart Award for Excellence in Chemistry, 1988; Arthur C. Cope Scholar Award, 1990; Alexander von Humboldt Stiftung Award, 1991; ASSU Teaching Award, 1991; Hoagland Prize for Undergraduate Teaching, Stanford, 1991; Fellow, American Academy of Arts and Sciences, 1992; Bing Teaching Award, Stanford, 1992; Pfizer Research Award for Synthetic Organic Chemistry, 1995; American Chemical Society Award for Creative work in Synthetic Organic Chemistry, 1998; Dean's Award for Distinguished Teaching, 2000; Fellow, American Association for the Advancement of Science, 2001; American Chemical Society H.C. Brown Award for Creative Research in Synthetic Methods, 2003; Member National Academy of Science, 2003; National Institutes of Health MERIT Award, 2006; The Hamilton Award (U. Nebraska), 2008; Tetrahedron Prize for Creativity in Organic Chemistry, 2012, Prelog Medal winner, 2013.

研究领域

Bioinorganic/Medicinal/Organic/Organometallic

Our research involves studies in chemistry, biology, medicine, and materials science. We are affiliated with the Medical School, Imaging Center, Chemical Biology Program and Molecular Therapeutics Program. A special emphasis is placed on training and research in synthesis, inventing new reactions, and the use of synthesis to address problems of significance in biology and medicine including eradication of HIV/AIDS, overcoming resistant cancer, and treating cognitive disorders like Alzheimer's disease. Our studies include: 1) the design and development of new reactions, methods, reagents, and strategies that introduce novel ways of synthesizing molecules of biological or medicinal significance; 2) synthetic and mechanistic organometallic chemistry with an emphasis on new catalytic reactions; 3) mode of action studies on medicinally important leads; 4) drug delivery and novel mechanisms of transport into cells including the design and development of new transporters of drugs and probes; 6) molecular imaging; 7) new therapeutic strategies to address unsolved medical problems; and 8) computer modeling and molecular recognition. The key to achieving the 'ideal synthesis' and greener chemistry is step economy which in turn relies critically on the discovery or invention of new reactions. New reactions are to synthesis what words are to language. Without expanding our lexicon we are limited in what we can do. Wender group members have discovered or invented over 25 new reactions including metal catalyzed 3+2, 4+4, 4+2, 5+2, 6+2, 6+1, 5+2+1, 4+2+2, 2+2+1, 5+1+2+1, 2+2+2+2 cycloadditions. New reactions are being used in the synthesis of new therapeutic leads, ligands for catalysis and materials. Another area of emphasis is the development of new strategies to treat disease. Current AIDS therapies stop disease progression by targeting the active virus. This is important but requires chronic treatment with associated cost, compliance and resistance problems. We seek to target the latent virus, a strategy which if successful could eradicate disease. These studies involve design, synthesis, mechanistic biology, and preclinical research. We are also investigating other medicinal leads selected for unique activity and special clinical promise like bryostatin, currently in clinical trials for the treatment of cancer. We have designed agents that are better than bryostatin in various assays and we can supply these agents through practical syntheses. Remarkably some of these agents facilitate learning in animal models of cognitive dysfunction. These are promising preclinical candidates for cancer and for Alzheimer's disease. Related opportunities at the interface of synthesis, biology and medicine include studies on daphnanes, gnidimacrin and apoptolidin, formidable synthetic challenges with unique clinical promise. A grand challenge in science is developing strategies for breaching biological barriers. In our studies, we use designed molecular transporters that enable passage of a wide range of molecules into cells, including small molecules, peptides, proteins, nucleic acids, and nanoparticles. This research opens new opportunities in chemotherapy and stem cell research and establishes a new tool of exceptional breadth for studying biochemical pathways and for real time imaging. It is being used in preclinical studies on overcoming resistant cancer.

近期论文

查看导师最新文章 (温馨提示:请注意重名现象,建议点开原文通过作者单位确认)

Wender, Paul A.; Fournogerakis, Dennis N.; Jeffreys, Matthew S.; Quiroz, Ryan V.; Inagaki, Fuyuhiko; Pfaffenbach, Magnus; "Structural Complexity Through Multicomponent Cycloaddition Cascades Enabled by Dual-Purpose, Reactivity Regenerating 1,2,3-Triene Equivalents", Nature Chemistry, 2014, 6, 448-452. Paul A. Wender, Fuyuhiko Inagaki, Magnus Pfaffenbach, Matthew C. Stevens, "Propargyltrimethylsilanes as Allene Equivalents in Transition Metal Catalyzed [5+2] Cycloadditions", Organic Letters, 2014, 16(11), 2923-2925. Wender, Paul A.; Lesser, Adam B.; Sirois, Lauren E.; "Rhodium Dinaphthocyclooctatetraene Complexes: Synthesis, Characterization and Catalytic Activity in [5+2] Cycloadditions", Angewandte Chemie, 2012, Published online: 1 Feb 2012. Wender, Paul A.; Lesser, Adam B.; Sirois, Lauren E., "The Preparation of Cyclohelpt-4-Enones by Rhodium Catalyzed Intermolecular [5+2] Cycloaddition" Organic Syntheses, 2011, 88, 109-120. Wender, Paul A.; Sirois, Lauren E.; Stemmler, René T.; Williams, Travis J. "Highly Efficient, Facile, Room Temperature Intermolecular [5+2] Cyclcoadditions Catalyzed by Cationic Rhodium(I): One Step to Cycloheptenes and Their Libraries" Organic Lett., 2010, 1604-1607. Liu, Peng; Sirois, Lauren E.; Cheong, Paul H.-Y.; Yu, Zhi-Xiang.; Hartung, Ingo, V.; Rieck, Heiko; Wender, Paul A.; Houk, Kendall N "Electronic and Steric Control of Regioselectivities in Rh(I)-Catalyzed (5+2) Cycloadditions: Experiment and Theory" J. Am. Chem. Soc., 2010, 10127-10135. Paul A. Wender, René T. Stemmler, Lauren E. Sirois, "A Metal-Catalyzed Intermolecular [5+2] Cycloaddition / Nazarov Cyclization Sequence and Cascade" J. Am. Chem. Soc., 2010, 2532-2533. Paul A. Wender, Justin P. Christy, Adam B. Lesser, and Marc T. Gieseler, "The Synthesis of Highly-Substituted Cyclooctatetraene Scaffolds by Metal-Catalyzed [2+2+2+2] Cycloadditions: Studies on Regioselectivity, Dynamic Properties and Metal Chelation", Angewandte Chemie Int. Ed 2009, 7823-7826. Wender, Paul A., Strand, Daniel, “Cyclocarboamination of Alkynes with Aziridines: Synthesis of 2,3-Dihydropyrroles by a Catalyzed Formal [3+2] Cycloaddition”, JACS, 2009, 7528-7529. Croatt, Mitchell P.; Wender, Paul A.; "The Diene Effect: The Design, Development, and Mechaqnistic Investigation of Metal-Catalyzed Diene-yne, Diene-ene, and Diene-allene [2+2+1] Cycloaddition Reactions", Eur. J. Org. Chem., 2009, Volume 2010, Issue 1, Date: January 2010, Pages 19-32. Wender, Paul; Croatt, Mitch; Kuhn, Bjorn; "Rhodium(I)-Catalyzed [2+2], [2+2+2], and [2+2+2+2] Cycloadditions of Dienes or Alkynes with a Bis-ene", Organometallic, 2009, 28(20), 5841-5844. Liu, P.; Cheong, P. H.; Yu, Z.-X.; Wender, P. A.; Houk, K. N. "Substituent Effects, Reactant Preorganization, and Ligand Exchange Control the Reactivity in Rh(I)-Catalyzed (5+2) Cycloadditions between Vinylcyclopropanes and Alkynes"; Angew. Chem. Int. Ed. 2008, 47, 3939-3941. Z.-X. Yu, P. Ha-Yeon Cheong, P. Liu, C. Legault, P. Wender, K. Houk “Origins of Differences in Reactivities of Alkenes, Alkynes, & Allenes in [Rh(CO)2Cl]2-Catalyzed (5+2) Cycloaddition Reactions with Vinylcyclopropanes” J. Am. Chem. Soc. 2008, 130, 2378-2379. Wender, P. A.; Christy, J. P. "Nickel(0)-Catalyzed [2 + 2 + 2 + 2] Cycloadditions of Terminal Diynes for the Synthesis of Substituted Cyclooctatetraenes" J. Am. Chem. Soc. 2007, 129, 13402-13403. Wender, P. A.; Paxton, T. J.; Williams, T. J.; "Cyclopentadienone Synthesis by Rhodium(I)-Catalyzed [3 + 2] Cycloaddition Reactions of Cyclopropenones and Alkynes" J. Am. Chem. Soc. 2006, 128, 14814-14815. Wender P. A.; Croatt, M. P.; Witulski, B. " New reactions and step economy: the total synthesis of (+/-)-salsolene oxide based on the type II transition metal-catalyzed intramolecular [4+4] cycloaddition" Tetrahedron 2006, 62, 7505-7511. Wender P. A.; Deschamps, N. M.; Sun R. "Rh(I)-Catalyzed C-C Bond Activation: Seven-Membered Ring Synthesis by a [6+1] Carbonylative Ring-Expansion Reaction of Allenylcyclobutanes" Agnew. Chem. Int. Ed. 2006, 45, 3957-3960. Wender, P. A.; Christy, J. P. "Rhodium(I)-Catalyzed [4+2+2] Cycloadditions of 1,3-Dienes, Alkenes, and Alkynes for the Synthesis of Cyclooctadienes" J. Am. Chem. Soc. 2006, 128, 6530-6531. Wender, P. A.; Haustedt, L. O.; Lim, J.; Love, J. A.; Williams, T. J.; Yoon, J.-Y. "Asymmetric Catalysis of the [5 + 2] Cycloaddition Reaction of Vinylcyclopropanes and Pi-Systems" J. Am. Chem. Soc. 2006, 128, 6302-6303. Wender, P. A.; Croatt, M. P.; Deschamps, N. M. "Metal-Catalyzed [2+2+1] Cycloadditions of 1,3-Dienes, Allenes, and CO" Angew. Chem. Int. Ed.2006, 45, 2459-2462.

推荐链接
down
wechat
bug